HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $23

Benzinga Newsdesk www.benzinga.com Neutral 50.8%

Neg 0% Neu 50.8% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $30 to $23.